By Fineline Cube 
Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for its XMVA09 injection, targeting wet age-related macular degeneration (wAMD). This marks a significant step in the development of novel gene therapies for this condition.
XMVA09 Mechanism
XMVA09 utilizes an AAV gene vector carrying VEGF-A and Ang-2 bispecific antibody genes. Administered via intravitreal injection, the therapy directly targets retinal pigment epithelial (RPE) cells. By expressing therapeutic proteins, XMVA09 aims to provide long-term treatment for wAMD.
Clinical Progress
The drug completed enrollment and treatment of all subjects in a Phase I study in April of the previous year. Preliminary results indicated good safety and tolerability, laying the groundwork for the Phase II clinical study.-Fineline Info & Tech